Translating Data Science:
Practical Implications for
AI and Machine Learning
Discussant: Philippe Salphati, Pharm.D.,
President & CEO, AYA Consulting; Member, Tefen Group
Growth in the use of artificial intelligence and machine learning by life science companies and researchers will revolutionize the field of biotechnology. The use of AI for drug discovery, improvement and enhancement of diagnostics, and as laboratory research assistants promises to dramatically reduce the costs and time spent on research and development.
Among other applications, AI and machine learning are being used to help identify promising molecules, examine laboratory and clinical data, recognize drug targets, and pinpoint new or alternative indications for existing medicines, all at dramatically increased speed, freeing up researchers for higher level work.
Artificial intelligence permits massive amounts of data to be examined and processed much more rapidly than human researchers are capable of doing. The algorithms inherent in artificial intelligence facilitate continued improvement in the accuracy, scope and speed of the data analyzed through machine learning. This helps to accelerate the targeting of particular molecules while improving the accuracy of diagnostics, leading to better patient outcomes.
The use of big data in pharmaceutical research inherently includes large amounts of personal health information collected from test subjects and patients. Although this information can be de-identified, the growing focus on individuals’ right to privacy creates a challenge for researchers.
This webinar will examine the growth in the use of artificial intelligence, the limits on the use of personal health information presented by laws governing privacy rights, and the intersection of the two. Special emphasis will be placed on the European Union’s recently implemented General Data Protection Regulation (GDPR) and the far-reaching impact it has on life science companies based in the United States.
About Our Speaker:
Brian Hand, Partner, Nordlicht & Hand
Mr. Hand is an attorney with over 30 years of experience representing biotech and pharmaceutical companies, as well as companies in other industries, across a broad spectrum of areas. His areas of practice include: working with companies on the commercial exploitation of intellectual property rights relevant to life science companies, including licensing, research and development collaborations and commercial contracts; equity and debt financing; mergers and acquisitions; corporate governance; executive employment and compensation; and employee relations.
Mr. Hand serves as a member of the Board of Directors and corporate Secretary of a number of companies. He is a member of the Bar of the State of New York and the Business, International and Science and Technology Law sections of the American Bar Association.